

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 September 2025 (11.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/186705 A8



(51) International Patent Classification:
A61K 39/09 (2006.01) *A61P 31/04* (2006.01)
A61K 47/64 (2017.01)

(21) International Application Number:
PCT/IB2025/052302

(22) International Filing Date:
03 March 2025 (03.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/561,954 06 March 2024 (06.03.2024) US
63/754,947 06 February 2025 (06.02.2025) US

(71) Applicant: **PFIZER INC.**, [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(72) Inventors: **GALLAGHER, Caitlyn**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **GU, Jianxin**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **KANEVSKY, Isis**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **MORAN, Justin Keith**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **SINGH, Suddham**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **THANNA, Sandeep**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., Legal Division, 66 Hudson Boulevard East, 11th Floor, New York, New York 10001-2192 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(48) Date of publication of this corrected version:

02 October 2025 (02.10.2025)

(15) Information about Correction:

see Notice of 02 October 2025 (02.10.2025)

(54) Title: IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF

(57) Abstract: The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.



WO 2025/186705 A8